The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled ``Cytomegalovirus in Transplantation: Developing Drugs to Treat or Prevent Disease.'' The purpose of this guidance is to assist sponsors in all phases of development of drugs and biologics for the treatment or prevention of cytomegalovirus (CMV) disease in patients who have undergone solid organ transplantation (SOT) or hematopoietic stem cell transplantation (HSCT).
Document
Cytomegalovirus in Transplantation: Developing Drugs To Treat or Prevent Disease; Draft Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled ``Cytomegalovirus in Transplantation: Developing Drugs ...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
83 FR 23463
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Cytomegalovirus in Transplantation: Developing Drugs To Treat or Prevent Disease; Draft Guidance for Industry; Availability,” thefederalregister.org (May 21, 2018), https://thefederalregister.org/documents/2018-10733/cytomegalovirus-in-transplantation-developing-drugs-to-treat-or-prevent-disease-draft-guidance-for-industry-availability.